From Fox News: High-dose vitamin B3 (niacin) may enhance immune activity and improve short-term disease control in glioblastoma when added to standard therapy, according to early preclinical studies.
Glioblastoma is a highly aggressive, fast-growing brain cancer that develops from cells in the brain and spinal cord.
In previous laboratory experiments in mice, niacin was shown to extend survival. Researchers at the University of Calgary aimed to determine whether that same benefit extended to humans.
The trials included 24 patients with glioblastoma, which has a median survival of roughly 12 to 18 months.
Six months after receiving niacin in addition to standard treatments (surgery, radiation and chemotherapy), 82% of the patients showed no disease progression, compared to the typical 54%, according to the study’s press release.
More from a press release by the University of Calgary:
The research is led by two members of both the Hotchkiss Brain Institute and Arnie Charbonneau Cancer Institute — Dr. Gloria Roldan Urgoiti, MD, PGME’16, an oncologist specialized in brain cancers, and Dr. Wee Yong, PhD, a neuroscientist whose research focuses on immune effects on the brain. Together, they designed a study to investigate whether niacin could rejuvenate compromised immune cells to kill tumour cells. The research began in the Yong lab, with mice, where findings showed niacin prolonged survival. That work evolved into a Phase I and II clinical trial.
“Normally, the immune system will try to counter and prevent tumour growth; however, this brain cancer supresses the immune system,” says Yong, a professor at the Cumming School of Medicine (CSM). “Niacin treatment rejuvenates immune cells so they can do what they are supposed to do, attack and kill the cancer cells. I see it as an ongoing ‘battle for the brain.’”
The findings were published in the Journal of Neuro-Oncology.
READ MORE from Fox News.
Follow us on X (Formerly Twitter.)
The DML News App: www.X.com/DMLNewsApp
The Dennis Michael Lynch Podcast archive is available below, with the most recent on top. Never miss an episode. Subscribe to the show by downloading The DML News App or go to Apple Podcasts.
